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Abstract
The immune checkpoint inhibitors have significantly modified the therapeutic landscape of advanced non-small cell lung
cancer in second-line and, more recently, first-line settings. Because of the superior outcome with pembrolizumab as an
upfront strategy, PD-L1 status should now be considered a new reflex biomarker for guiding first-line treatment in
patients with advanced non-small cell lung cancer. Improved responses have also been reported with the combination of
immune checkpoint inhibitors and chemotherapy as the first-line treatment; however, this strategy has not yet been
validated by phase III trial data and its interplay with PD-L1 status still requires clarification.
In this manuscript we review the contradictory results of recent phase III trials with immune checkpoint inhibitors in the
first-line setting, the potential reasons for discrepancies, and some of the remaining open questions related to the
positioning of immune checkpoint inhibitors in the first-line setting of non-small cell lung cancer.
Keywords: Immunotherapy, Pembrolizumab, Nivolumab, PD-1, PD-L1, First-line, Non-small cell lung cancer
Introduction
First-line platinum-based chemotherapy is the standard
of care in the majority of patients with advanced non-
small cell lung cancer (NSCLC) without comorbidities
and with optimal performance status (PS) [1]. This
excludes patients with oncogenic driver alterations, such
as the epidermal growth factor receptor (EGFR) muta-
tion (in almost 50% of patients of Asian ethnicity com-
pared to 15% in the Caucasian population [2]) or the
anaplastic lymphoma kinase (ALK) re-arrangement (in
5% patients independently of ethnicity [3]) that can be
treated with tyrosine kinase inhibitors. However, even in
the era of maintenance therapy, platinum-based chemo-
therapy results in a median progression-free survival
(PFS) of ~6 months and a response rate (RR) of ~30%
[1]. Therefore, significant advances are eagerly awaited.
A deeper understanding of tumor-immune interac-
tions and development of immune checkpoint inhibitors
has dramatically changed the therapeutic landscape of
NSCLC and other malignancies. The immune system rec-
ognizes and is poised to eliminate cancer [4]. Immune
checkpoints refer to a variety of inhibitory pathways that
are crucial for regulating the duration and amplitude of
physiological immune responses in peripheral tissues in
order to minimize collateral tissue damage [5]. However,
these immune checkpoint pathways can be co-opted by
cancer cells, circumventing immune destruction [4],
which is a hallmark of cancer [6]. In NSCLC, expression
of programmed death ligand-1 (PD-L1, B7-H1) reflects an
immune-active microenvironment and is a mechanism for
evading elimination by the immune system [7]. Exhausted
T-cells in the microenvironment show overexpression of
programmed cell death protein 1 (PD-1), which binds to
PD-L1 and decreases effector cytokine production and
cytolytic activity, leading to the failure of cancer elimin-
ation [8]. This knowledge has prompted the development
of immune checkpoint inhibitors – different monoclonal
antibodies that bind either to PD-1 or PD-L1 and hamper
immune evasion – as new treatment strategies in
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Four randomized phase III trials have reported a sta-
tistically significant improvement in overall survival (OS)
with immune checkpoint inhibitors compared with do-
cetaxel in patients with platinum-refractory advanced
NSCLC: the CheckMate017 trial [9] in patients with
squamous NSCLC; the CheckMate057 [10] in patients
with non-squamous NSCLC (both trials testing nivolu-
mab, a monoclonal-antibody anti-PD-1); the KEYNOTE-
010 phase II/III trial [11] with pembrolizumab, which
also binds to PD-1 (inclusion restricted to patients with
at least 1% PD-L1 expression on tumor cells); and the
OAK trial [12] with atezolizumab, a monoclonal anti-
body against PD-L1. Of note, in the KEYNOTE 010
study [11], the magnitude of benefit with pembrolizu-
mab correlated with PD-L1 expression, with increased
benefit seen in patients with tumors with strong PD-L1
expression, defined as expression on at least 50% of
tumor cells, regardless of the staining intensity with the
22C3 clone [11]. On the basis of these trials, the US
Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) have approved nivolumab and
pembrolizumab as second-line therapy, the latter re-
stricted to tumors expressing PD-L1. The FDA has also
recently approved atezolizumab for the management of
previously treated patients with advanced NSCLC. In the
absence of head-to-head comparisons or clear biological
differences between these agents, and no significant dif-
ferences in toxicity profile (except a slight increase in
immune-related adverse events (AEs) and pneumonitis
with anti-PD-1 inhibitors) [13], it is not possible to rec-
ommend one treatment over another.
The 3-year OS of patients with advanced NSCLC treated
with these drugs after failure with platinum-based chemo-
therapy is approaching 20% [14]. This response, along with
an improved safety profile, has prompted increasing interest
in testing these agents in the first-line setting.
Anti-PD-1 antibodies as single agent in patients
with PD-L1-positive NSCLC
Pembrolizumab
The phase III KEYNOTE 024 trial comprises patients with
advanced and strongly PD-L1-positive NSCLC [15]. A total
of 1942 patients were screened for enrolment; 1653 had
evaluable samples, and 500 (30.2%) of patients had tumors
with PD-L1 expression ≥50%. A total of 305 patients who
met inclusion criteria were randomized to pembrolizumab
(200 mg every 3 weeks for up to 35 cycles or until docu-
mented progressive disease) versus four to six cycles of
standard of care platinum-based chemotherapy (platinum/
pemetrexed, platinum/gemcitabine, or carboplatin/pacli-
taxel) as first-line treatment. Pemetrexed maintenance ther-
apy was received by 30% of patients with non-squamous
histology. In addition, 43.7% of patients in the control arm
crossed over per protocol to pembrolizumab upon disease
progression. Patients were excluded from the trial if they
were harboring EGFR mutations or ALK translocations,
had an Eastern Cooperative Oncology Group (ECOG) per-
formance status ≥2, had untreated brain metastasis, or were
receiving any dose of oral steroids for an autoimmune dis-
ease. The primary endpoint of the trial was the median
PFS. Compared with standard first-line platinum-based
chemotherapy, pembrolizumab significantly improved the
primary endpoint from 6.0 months to 10.3 months (hazard
ratio [HR] 0.50, 95% confidence interval [CI] 0.37–0.68, p <
0.001). The RR according to Response Evaluation Criteria
In Solid Tumors (RECIST; 44.8% versus 27.8%, p < 0.001)
and OS (not reached in both arms, HR 0.60, 95% CI 0.41–
0.89, p = 0.005) were also improved, with 1-year OS of 70%
versus 54% [15]. The benefit of pembrolizumab with
respect to PFS was evident in all subgroups examined
according to gender, age, histology, smoking status, and
brain metastases at baseline. However, the benefit was
lower in female and never-smoker patients (probably re-
lated to the lower mutational load in this population [16]),
and the greatest benefit to PFS was observed in patients
with squamous histology (HR 0.35, 95% CI 0.17–0.71).
Grade 3, 4, or 5 treatment-related AEs also favored pem-
brolizumab (26.6% versus 53.3%). The incidence of grade
3–4 immune-mediated AEs was 9.7% with pembrolizumab
[15]. Pembrolizumab had a clinically meaningful improve-
ment in quality of life compared to platinum-based chemo-
therapy [17] (Table 1).
The magnitude of benefit in the control arm was con-
sistent with historic controls [18], suggesting that pembro-
lizumab efficacy is not overestimated for an ineffective
control arm. However, it is unknown whether the survival
benefit was because pembrolizumab treatment is intrinsic-
ally more potent as a first-line treatment or because cross-
over was limited to <50% of the patients in the control
arm. Indeed, trials in patients with EGFR-mutant or ALK-
rearranged NSCLC have had much higher rates of cross-
over from chemotherapy to personalized treatment after
platinum-based chemotherapy progression (65% in EGFR-
mutant [19] and 70% in ALK-positive populations [20]),
leading to a lack of survival differences between treatment
arms. The clear benefit for OS could also be due to a
potentially lower efficacy of pembrolizumab in platinum-
pretreated patients than in chemonaïve patients, whereas,
in the same settings, targeted therapies yield the same
benefit [21, 22].
In the KEYNOTE 024 trial, 11.7% of patients in the
pembrolizumab arm had previously treated brain metas-
tases at baseline. The PFS benefit in this subgroup was
similar to those patients without brain metastases at
baseline (HR 0.55 versus HR 0.50). The efficacy of pem-
brolizumab in patients with PD-L1 positive (>1%)
NSCLC with untreated or progressive asymptomatic
brain metastases between 5 and 20 mm of diameter has
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also recently been tested in a phase II trial that reported
a cerebral response rate of 33%. The median duration of
confirmed brain responses was 6 months [23]. Approxi-
mately 17% of NSCLC patients have brain metastases at
baseline [24]. In our opinion, supra-tentorial asymptom-
atic brain metastases should not be considered exclusion
criteria for immune checkpoint inhibitor treatment. The
risk of brain metastases increases over time owing to the
prolonged survival of patients with advanced NSCLC
[25]. Therefore, further investigations are needed to de-
termine optimal treatment combinations with brain
radiotherapy, sequences of treatment, and safety [26].
Globally, pembrolizumab results from KEYNOTE 024
[15] were consistent with the efficacy observed in the
KEYNOTE 001 [27] study in the subgroup of chemona-
ïve patients. The FDA approved pembrolizumab in the
first-line setting in this population on 24 October 2016,
and on 15 December 2016, the EMA Committee for
Medicinal Products for Human Use also approved pem-
brolizumab as monotherapy in the first-line setting of
metastatic NSCLC in adults whose tumors express PD-
L1 in a tumor proportion score (TPS) ≥50% and who
have no EGFR- or ALK-positive tumor mutations. The
efficacy of pembrolizumab as a first-line treatment in
NSCLC patients with PD-L1 expression <50% remains
unknown. The ongoing phase III KEYNOTE 042 study
(NCT02220894) will assess the survival benefit of pem-
brolizumab over standard first-line platinum-based
chemotherapy in treatment-naïve patients who have tu-
mors with ≥1% PD-L1 positivity. Stratification according
to PD-L1 expression (strong [≥50%] versus weak [1–49%])
will be performed in the study.
Among the 30% of patients whose tumors express PD-
L1 with a TPS ≥ 50%, other clinical exclusion criteria limit
the extended use of pembrolizumab in the first-line set-
ting, for example exclusion of patients considered unfit or
with poor PS (representing almost 34% of NSCLC patients
in contemporary cohorts [28]), patients with EGFR-mu-
tant and ALK-rearranged tumors (approximately 17% of
adenocarcinoma lung cancers in Caucasian populations
[29]), and the absence of steroids or autoimmune disor-
ders (13.5% of lung cancer patients [30]). As such, the
pool of patients eligible for upfront pembrolizumab is cer-
tainly not 30% of all chemonaïve patients with NSCLC
(which represents the percentage of frontline patients
whose tumors express PD-L1 with a TPS ≥ 50%), but
probably closer to 10% of them. This pool clearly needs to
be enlarged.
Moreover, the turnaround time from patient selection
to treatment, based on PD-L1 expression, is not reported
in KEYNOTE 024 but is expected to be frequently lon-
ger than one month. There is a high probability that pa-
tients with relatively indolent disease were favored for
inclusion in the study, adding another bias compared to
routine practice. Patients with a poorer prognosis need
to be explored, such as in the ongoing phase II trial
NCT02879617 evaluating first-line durvalumab in PS2
patients with advanced NSCLC.
Nivolumab
The phase III CheckMate 026 trial tested the efficacy of
nivolumab compared to standard first-line chemotherapy
(platinum/pemetrexed, platinum/gemcitabine, or carbo-
platin/paclitaxel) in 423 patients with PD-L1-positive
(≥5% of expression by 28–8 clone) advanced NSCLC [31].
Patients harboring EGFR mutations or ALK translocations
were ineligible. Patients with adequately treated brain me-
tastases were allowed. No imbalances were reported in ei-
ther arms regarding brain metastases (~12%), histology
(~24% of squamous), ECOG performance status (~30%
PS0), or current smokers (~20% in both arms). A higher
proportion of females was included in the chemotherapy
arm (45.2% versus 32.1%). Maintenance treatment was
prescribed in 38% of patients [31]. No benefit was seen
with nivolumab compared to chemotherapy in terms of
the primary endpoints PFS (4.2 versus 5.9 months, HR
1.15, 95% CI 0.91–1.45, p = 0.251), OS (14.4 versus
13.2 months, HR 1.02, 95% CI 0.80–1.30), or RR (26.1%
Table 1 Immune checkpoint inhibitors in first-line treatment in advanced non-small cell lung cancer patients
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versus 33.5%). However, the toxicity profile favored nivo-
lumab, with 17.6% of patients having grade 3–4 AEs com-
pared with 50.6% in the chemotherapy arm (Table 1). Of
note, patients with NSCLC with strong PD-L1 expression
(TPS ≥ 50%) did not derive a greater benefit from nivolu-
mab than those with weaker expression. Nivolumab was
the post-discontinuation treatment in 60% of the patients
in the chemotherapy arm. The lack of survival benefit
could be related to various hypothetical factors. First,
there was a higher proportion of tumors with strong PD-
L1 expression (TPS ≥ 50%) in the control arm compared
to the nivolumab arm (74.1% versus 53.2%). Second, only
44% of patients in the nivolumab arm received second-
line treatment, mostly platinum-based chemotherapy, sug-
gesting that a certain subgroup of patients was untreated
[31]. This could be a consequence of hyper-progressive
diseases on immunotherapy, as recently reported by
Champiat et al. [32]. Overall, results from Check-Mate 26
in the whole population and for those tumors with
strongly positive PD-L1 expression are inconsistent with
first-line nivolumab performance in phase I/II trials [33].
Although the reason for these contrasting results be-
tween KEYNOTE 024 [15] and Checkmate 026 [31] trial
remains unclear, we should considered the nivolumab
trial as negative, and we believe that differences in pa-
tient selection are the primary causes of this discrepancy.
Differences in biomarker tests and in PD-L1 expression
cut-off point (22C3 and 50% with pembrolizumab versus
28–8 clone and 5% with nivolumab) could have contrib-
uted to the discordant results between the trials. This
means that patients with strong PD-L1 positivity in the
KEYNOTE trial may not be similar to patients with
strong PD-L1 positivity in the Checkmate trial, because
the sensitivity of the relevant clones used to define PD-
L1 status is potentially different. Additionally, PD-L1
testing was performed after metastatic diagnosis in the
pembrolizumab trial, whereas in the nivolumab trial it
was performed in archival tissue biopsy specimens taken
within 6 months prior to randomization. However, in
the KEYNOTE 010 trial, survival benefit with pembroli-
zumab as a second-line treatment was independent of
whether the PD-L1 test was performed in an archival or
in a new tissue biopsy specimen [11]. The efficacy of im-
mune checkpoint inhibitors is higher among smokers
[16]. A higher percentage of never-smoker patients was
included in the nivolumab trial than in the pembrolizu-
mab trial (11% versus 3%); such patients have lower mu-
tational loads that negatively correlate with the success
of immune checkpoint-targeting therapies [34]. Another
major difference between the trials was the percentage
of patients who received prior radiotherapy and were en-
rolled in the trial. This percentage was abnormally high
(37.6%) for patients enrolled in the CheckMate 026 trial
[31]. In the KEYNOTE 024 [15] trial, prior radiation
therapy of >30 Gy within 6 months of the first dose of
trial treatment was an exclusion criterion. Therefore,
sites that were involved in both trials may have oper-
ationally favored enrolment of all previously irradiated
patients in to Checkmate026. It is clear that previous
radiotherapy can have major consequences on the tumor
microenvironment [35] and potentially lead to decreased
activity of immune checkpoint inhibitors in previously
irradiated areas. At this stage it is unknown which areas
(mediastinum, others) were previously irradiated in pa-
tients enrolled in the Checkmate 026 trial [31].
Other first-line randomized phase III clinical trials
are testing anti-PD-1 monotherapy, such as nivolumab
in CheckMate 227 (NCT02477826), or anti-PD-L1
monotherapies, such as atezolizumab in IMpower 110
(NCT02409342) and avelumab in the ongoing JAVELIN
Lung 100 trial (NCT02576574). These trials may validate
immune checkpoint inhibitors as a first-line treatment in
patients with PD-L1-positive NSCLC.
Combination of anti-PD-1 antibodies with
chemotherapy
A large body of preclinical data has shown that chemo-
therapy and radiation modulate the immune response
against tumors [36], and that chemotherapy can induce
PD-L1 expression in tumor cells [37, 38],. This has led
to clinical investigation of combinations of immune
checkpoint inhibitors and chemotherapy.
The phase II KEYNOTE-021 trial (n = 123) compared
pembrolizumab 200 mg for 2 years concomitant with four
cycles of carboplatin-pemetrexed chemotherapy followed
by pemetrexed as maintenance therapy with chemotherapy
alone [39]. A higher proportion of never-smoker patients
(25% versus 14%) and patients with adenocarcinoma
histology (97% versus 87%) were included in the pembroli-
zumab arm.
A total of 32% of patients in the chemotherapy group
crossed over to receive pembrolizumab monotherapy as
allowed by the study protocol. The combination arm had
improved RR (55% versus 29%, p = 0.0016, with 80% RR
among strongly PD-L1-positive tumors) and PFS
(13.0 months versus 8.9 months, HR 0.53, 95% CI 0.31–
0.91, p = 0.010) compared to chemotherapy alone; however,
the frequency of grade 3–4 treatment-related AEs was
higher in the concomitant arm (39% versus 26%; Table 1).
Of note, the chemotherapy arm also demonstrated impres-
sive PFS, suggesting a high level of patient selection. Indeed,
median PFS was much longer than in similar populations
included in other trials with the same chemotherapy sched-
ule, such as the POINTBREAK trial (5.6 months) [40]. The
KEYNOTE 021 study [39] reported a shorter time to
response in the combination arm compared to the chemo-
therapy alone arm (1.5 months versus 2.7 months), suggest-
ing this approach could be a good strategy for symptomatic
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patients [39]. These results are similar to those previously
reported in phase I trials, suggesting that combination
treatment could be an optimal strategy.
Overall, while very promising, these results need to be
validated in a phase III trial. The preliminary RR of 80%
in patients with tumors harboring PD-L1 expression
≥50% treated with the combination therapy appears
intriguing, but numbers are too small to draw any
definitive conclusions. The ongoing phase III trials
KEYNOTE-189 (NCT02578680) and KEYNOTE-407
(NCT02775435) with pembrolizumab; and the IMpower
132 (NCT02657434), IMpower 130 (NCT02367781),
IMpower 131 (NCT02367794), and IMpower 150
(NCT02366143) trials with atezolizumab are testing com-
bination treatment versus standard of care and could help
clarify the best treatment strategy for this population.
Other open questions in the in first-line setting
The third approach to position immunotherapy in the
first-line setting is the combination of PD-1/PD-L1
blockade with anti-cytotoxic T-lymphocyte-associated
protein 4 (CTLA-4) compounds (Fig. 1).
Early preclinical studies have suggested that combined
CTLA-4 and PD-1 pathway blockade produces synergistic
anti-tumor activity [5, 41], providing the rationale for
clinical studies. The high efficacy of nivolumab plus ipili-
mumab has been recently reported in PD-L1-positive
tumors [42] (Table 1). The phase III CheckMate 227
(NCT02477826) trial with nivolumab plus ipilimumab, and
the MYSTIC (NCT02453282) and NEPTUNE
(NCT02542293) trials with durvalumab plus tremelimu-
mab are comparing this strategy to anti-PD-1/PD-L1
monotherapy or chemotherapy. The toxicity profiles of
these combinations might, however, limit their applicability.
The optimal strategy for NSCLC patients with tumor
PD-L1 expression <50% has to be better defined: poten-
tial candidate therapies include concomitant treatments
with chemotherapy, a combination of immune check-
point inhibitors, or sequential strategies. This issue is
important because of the limited standard second-line
options currently available [43, 44] in cases in which
immune checkpoint inhibitors are prescribed as the
first-line treatment.
The treatment duration with immune checkpoint in-
hibitors is an important issue as well as economic costs.
Therefore, detailed health economic analysis are needed
to avoid inequities to access for these treatments [45].
New tools should be applied, such as the ESMO Magni-
tude of Clinical Benefit Scale (ESMO-MCBS), which
uses a rational, structured, and consistent approach to














































































Fig. 1 Upcoming randomized immunotherapy trials in first-line NSCLC and projected read-out timelines
Remon et al. BMC Medicine  (2017) 15:55 Page 5 of 7
derive a relative ranking of the magnitude of clinically
meaningful benefit that can be expected from new anti-
cancer therapies [46, 47].
Conclusions
Immune checkpoint inhibitors are the standard of care
for second-line treatment in advanced NSCLC, and
pembrolizumab should be considered a standard first-
line treatment in NSCLC patients with a good PS whose
tumors have PD-L1 expression ≥50%. PD-L1 status
determined by immunohistochemistry should be consid-
ered a reflex biomarker, along with EGFR mutation and
ALK translocation, for guiding treatment of front-line
patients with advanced NSCLC.
Discrepancies in patient selection (notably, previous
radiotherapy) and PD-L1 testing methods could explain
the negative results achieved with nivolumab in the first-
line setting. Better outcomes were observed with chemo-
therapy combined with pembrolizumab compared to
chemotherapy alone in a small-randomized phase II trial.
Whether this strategy is better than immunotherapy alone
or the combination of different checkpoint inhibitors
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